Literature DB >> 21717473

Peripheral arterial disease--what do we need to know?

Madhan Shanmugasundaram1, Vinny K Ram, Ulrich C Luft, Molly Szerlip, Joseph S Alpert.   

Abstract

Peripheral artery disease (PAD) results from progressive narrowing of arteries secondary to atherosclerosis and is defined as an Ankle Brachial Index of <0.9. PAD is highly prevalent and is an increasing burden on both the economy and the patient, especially given the rapid shift in demographics in the United States. Despite its prevalence and association with cardiovascular disease, PAD is still underdiagnosed and undertreated. This may, in part, be related to lack of recognition from the physician's side or paucity of evidence from clinical trials. It has been shown that medical therapy approved for cardiovascular disease is effective in the treatment of PAD and decreases cardiovascular events. Various revascularization strategies are also available for improving symptoms and quality of life in these patients, yet they are underutilized. In an attempt to increase its recognition, PAD has been considered a coronary artery disease equivalent. This article reviews the diagnosis and management of PAD.
© 2011 Wiley Periodicals, Inc. The authors have no funding, financial relationships, or conflicts of interest to disclose. © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21717473      PMCID: PMC6652699          DOI: 10.1002/clc.20925

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  7 in total

1.  Endovascular therapy of axillary artery disease with drug-coated balloon angioplasty.

Authors:  Subhi J Al'Aref; Rajesh V Swaminathan; Dmitriy N Feldman
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-10

2.  Association between Plaque Score of the Carotid Artery and the Severity of Sleep Apnea Syndrome in Patients with Chronic Kidney Disease.

Authors:  Daisuke Hasegawa; Akihito Tanaka; Daijo Inaguma; Eri Ito; Naoki Kamegai; Akiko Kato; Minami Mizutani; Hiroya Shimogushi; Hibiki Shinjo; Yasuhiro Otsuka; Asami Takeda
Journal:  Cardiorenal Med       Date:  2016-02-05       Impact factor: 2.041

Review 3.  Diabetes-associated macrovascular complications: cell-based therapy a new tool?

Authors:  Maddalena Gili; Alberto Orsello; Sara Gallo; Maria Felice Brizzi
Journal:  Endocrine       Date:  2013-03-30       Impact factor: 3.633

4.  Hypoxia-induced miR-210 modulates tissue response to acute peripheral ischemia.

Authors:  Germana Zaccagnini; Biagina Maimone; Valeria Di Stefano; Pasquale Fasanaro; Simona Greco; Alessandra Perfetti; Maurizio C Capogrossi; Carlo Gaetano; Fabio Martelli
Journal:  Antioxid Redox Signal       Date:  2013-10-16       Impact factor: 8.401

5.  Economic Implications of Preventing Major Cardiovascular and Limb Events with Rivaroxaban plus Aspirin in Patients with Coronary or Peripheral Artery Disease in the United States.

Authors:  Luis Hernandez; Anshul Shah; Qi Zhao; Dejan Milentijevic; Akshay Kharat
Journal:  Am Health Drug Benefits       Date:  2020 Oct-Nov

6.  Fucoidan Stimulates Monocyte Migration via ERK/p38 Signaling Pathways and MMP9 Secretion.

Authors:  Elene Sapharikas; Anna Lokajczyk; Anne-Marie Fischer; Catherine Boisson-Vidal
Journal:  Mar Drugs       Date:  2015-06-30       Impact factor: 5.118

7.  Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry.

Authors:  Jérémie Abtan; Deepak L Bhatt; Yedid Elbez; Emmanuel Sorbets; Kim Eagle; Christopher M Reid; Iris Baumgartner; David Wu; Mary E Hanson; Hakima Hannachi; Puneet K Singhal; Philippe Gabriel Steg; Gregory Ducrocq
Journal:  Clin Cardiol       Date:  2017-05-18       Impact factor: 2.882

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.